Bavarian Nordic raised the company’s financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersBavarianNordic6-10-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-10 07:00:042022-06-10 11:45:21Bavarian Nordic raises outlook for third time buoyed by U.S. vaccine order
